Covid: Large trial of new treatment begins in UK

0 5



FEED THE POOR

Feeding the poor and needy is an act that draws us closer to Allah. We earn His forgiveness, mercies and blessings through this act of charity.

“Anyone who looks after and works for a widow and a poor person is like a warrior fighting for Allah?s cause, or like a person who fasts during the day and prays all night. (Bukhari)

By Justin Rowlatt




Source: BBC




A large-scale trial of a new treatment it is hoped will help stop Covid-19 patients from developing severe illness has begun in the UK.




The first patient received the treatment at Hull Royal Infirmary on Tuesday afternoon.




Support Islam Religion Guardian
At the present time, we are running on very limited funds. In order for us to run Islam Religion Guardian service efficiently, we are in need of your generous support.

It involves inhaling a protein called interferon beta which the body produces when it gets a viral infection.




The hope is it will stimulate the immune system, priming cells to be ready to fight off viruses.




Early findings suggested the treatment cut the odds of a Covid-19 patient in hospital developing severe disease – such as requiring ventilation – by almost 80%.




It was developed at Southampton University Hospital and is being produced by the Southampton-based biotech company, Synairgen.




A course of treatment with the new drug could cost around £2,000, which is not that expensive for a hospital treatment.




“To be viable it will have to represent good value for money,” Synairgen’s chief executive Richard Marsden said.




Alexandra Constantin, 34, was the first person to receive the treatment as part of this new trial, after she was admitted to the hospital with coronavirus on Monday.




Read further

Subscribe to our newsletter
Sign up here to get the latest news, updates delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy